Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan.
The purpose of this study was to retrospectively clarify the current status in Japan of TACE using Lipiodol together with anticancer agents to treat hepatocellular carcinoma (HCC). We retrospectively surveyed 4,659 (average annual total) procedures for HCC over the years 2002-2004 at 17 institutions included in the TACE Study Group of Japan. The survey included six questions that were related mainly to TACE and Lipiodol for HCC treatment. The most frequently applied among the 4,659 procedures at the 17 institutions were TACE (2,310; 50%) and local ablation (1,395; 30%). Five of the institutions applied 201-300 procedures and 4 applied 101-200. Lipiodol was used in "all procedures" and in "90% or more" at seven and nine institutions, respectively. Almost all institutions applied 4-6 (mean, 5) ml of Lipiodol during TACE to treat tumors 5 cm in diameter. In conclusion, this survey clarified that TACE using Lipiodol and anticancer agents is a popular option for HCC treatment in Japan.
Satake
Mituo
M
Department of Diagnostic Radiology, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan, msatake@ncc.go.jp.
Uchida
Hideo
H
Arai
Yasuaki
Y
Anai
Hiroshi
H
Sakaguchi
Hirosi
H
Nagata
Takashi
T
Yamane
Tomohiko
T
Kichikawa
Kimihiko
K
Osaki
Yukio
Y
Okazaki
Masatoshi
M
Higashihara
Hideyuki
H
Nakamura
Hironobu
H
Osuga
Keigo
K
Nakao
Norio
N
Hirota
Shouzou
S
D001707:Biopsy, Needle; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy*; D002404:Catheterization / Q000379:methods; D016461:Chemoembolization, Therapeutic / Q000706:statistics & numerical data*; D003287:Contrast Media / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D017723:Drug Utilization Review / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007459:Iodized Oil; D007564:Japan; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy*; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D003287:Contrast Media; D007459:Iodized Oil